May 5, 2020 / 12:58 PM / a month ago

BRIEF-DelMar Pharmaceuticals Provides Enrollment Update In Phase 2 Clinical Trial Of Val-083 For Adjuvant Treatment Of Brain Tumors

May 5 (Reuters) - DelMar Pharmaceuticals Inc:

* DELMAR PHARMACEUTICALS [NASDAQ:DMPI] PROVIDES ENROLLMENT UPDATE IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR ADJUVANT TREATMENT OF BRAIN TUMORS

* DELMAR PHARMACEUTICALS INC - PHASE 2 TRIAL MORE THAN 90% ENROLLED WITH ENROLLMENT CONTINUING EVEN IN LIGHT OF CORONAVIRUS PANDEMIC

* DELMAR PHARMACEUTICALS - ENROLLED 22 PATIENTS IN ADJUVANT ARM OF CO’S PHASE 2 CLINICAL STUDY INVESTIGATING ADJUVANT TREATMENT OF GBM WITH VAL-083 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below